Abstract
The burgeoning problem of drug resistance in malaria requires the urgent discovery of new drugs. Discovery of an antimalarial agent that fulfills the requirements of a mass-treatment drug is challenging. Such an antimalarial drug should be safe for infants and children, be efficacious during a treatment course of 3-5 days, have good intestinal absorption, and be inexpensive. Such conditions are difficult to meet, which explains (at least in part) the paucity of antimalarial drugs. Development of antimalarial drugs has been based on two orthodox approaches: drugs are discovered from medicinal plants or synthetic chemistry. However, recent observation of human chemotherapy and pharmacopeia suggests that other strategies could be used to discover new drugs or to extend the therapeutic lifetime of failing drugs. In this review, we present evidence that the use of modulators of the efficacy and toxicity of drugs will lead to the discovery of new drugs and extend the therapeutic lifetime of existing agents.
| Original language | English |
|---|---|
| Pages (from-to) | 277-283 |
| Number of pages | 7 |
| Journal | Trends in Pharmacological Sciences |
| Volume | 31 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2010 |
| Externally published | Yes |
Bibliographical note
Funding Information:We thank the Director of the Kenya Medical Research Institute for permission to publish this review. This study was supported by the European Developing Countries Clinical Trials Partnership (EDCTP).
ASJC Scopus subject areas
- Toxicology
- Pharmacology
